comparemela.com
Home
Live Updates
TargED Biopharmaceuticals raises EUR 39 Million in Series A
TargED Biopharmaceuticals raises EUR 39 Million in Series A
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients
/PRNewswire/ -- TargED Biopharmaceuticals ("TargED"), a private biotechnology company focused on developing improved treatments for thrombotic diseases, today...
Related Keywords
Norway ,
Germany ,
Munich ,
Bayern ,
Paris ,
France General ,
France ,
Stockholm ,
Sweden ,
Utrecht ,
Netherlands ,
United Kingdom ,
Belgium ,
Oslo ,
Austria ,
Velden ,
Amsterdam ,
Noord Holland ,
Belgian ,
German ,
Olivier Litzka ,
Thrombocytopenia Purpura ,
Andera Croissance ,
Thijs Cohen Tervaert ,
Jacob Lange Moresco ,
Roger Franklin ,
Kristof Vercruysse ,
Coen Maas ,
Marc Van Moorsel ,
Andera Life Sciences ,
University Medical Center Utrecht ,
Utrecht Health Seed Fund ,
European Life Sciences ,
Life Sciences ,
Department Of Clinical Chemistry ,
Andera Partners ,
Hadean Ventures ,
Inkef Capital ,
Sunstone Life Science Ventures ,
Biogeneration Ventures ,
Curie Capital ,
Utrecht Health Seed ,
Thrombotic Thrombocytopenia Purpura ,
Acute Ischemic Stroke ,
Chief Executive Officer ,
Jan Van ,
Sunstone Life Science ,
Cohen Tervaert ,
Associate Professor Coen Maas ,
Managing Partner ,
Targeted Enzyme ,
Associate Professor ,
Clinical Chemistry ,
Steven De Maat ,
Thrombotic Thrombocytopenic Purpura ,
Andera Midcap ,
Andera Expansion ,
Andera Acto ,
Andera Infra ,
Onward Medical ,
Targed Biopharmaceuticals ,